Your browser doesn't support javascript.
Susceptibility to COVID-19 in Patients Treated With Antimalarials: A Population-Based Study in Emilia-Romagna, Northern Italy.
Salvarani, Carlo; Mancuso, Pamela; Gradellini, Federica; Viani, Nilla; Pandolfi, Paolo; Reta, Massimo; Carrozzi, Giuliano; Sandri, Gilda; Bajocchi, Gianluigi; Galli, Elena; Muratore, Francesco; Boiardi, Luigi; Pipitone, Nicolò; Cassone, Giulia; Croci, Stefania; Marata, Anna Maria; Costantini, Massimo; Giorgi Rossi, Paolo.
  • Salvarani C; Azienda USL-IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Italy.
  • Mancuso P; Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
  • Gradellini F; Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
  • Viani N; Azienda USL di Modena and Azienda OU di Modena, Modena, Italy.
  • Pandolfi P; Azienda USL di Bologna, Bologna, Italy.
  • Reta M; Azienda USL di Bologna, Bologna, Italy.
  • Carrozzi G; Azienda USL di Modena, Modena, Italy.
  • Sandri G; Università di Modena e Reggio Emilia, Modena, Italy.
  • Bajocchi G; Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
  • Galli E; Università di Modena e Reggio Emilia, Modena, Italy.
  • Muratore F; Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
  • Boiardi L; Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
  • Pipitone N; Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
  • Cassone G; Università di Modena e Reggio Emilia, Modena, Italy.
  • Croci S; Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
  • Marata AM; Regione Emilia Romagna, Bologna, Italy.
  • Costantini M; Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
  • Giorgi Rossi P; Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Arthritis Rheumatol ; 73(1): 48-52, 2021 01.
Article in English | MEDLINE | ID: covidwho-696616
ABSTRACT

OBJECTIVE:

To evaluate the susceptibility to coronavirus disease 2019 (COVID-19) in patients with autoimmune conditions treated with antimalarials in a population-based study.

METHODS:

All residents treated with chloroquine (CQ)/hydroxychloroquine (HCQ) from July through December 2019 and living in 3 provinces of Regione Emilia-Romagna were identified by drug prescription registries and matched with the registry containing all residents living in the same areas who have had swabs and tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated.

RESULTS:

A total of 4,408 patients were identified. The prevalence of patients receiving antimalarials was 0.85 per 1,000 men and 3.3 per 1,000 women. The cumulative incidence of testing during the study period was 2.7% in the general population and 3.8% among those receiving CQ or HCQ, while the cumulative incidence of testing positive was 0.55% in the general population and 0.70% among those receiving CQ/HCQ. Multivariate models showed that those receiving CQ/HCQ had a slightly higher probability of being tested compared to the general population (OR 1.09 [95% CI 0.94-1.28]), the same probability of being diagnosed as having COVID-19 (OR 0.94 [95% CI 0.66-1.34]), and a slightly lower probability of being positive once tested (OR 0.83 [95% CI 0.56-1.23]). None of the differences were significant.

CONCLUSION:

Our findings do not support the use of antimalarials as a prophylactic treatment of COVID-19.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Autoimmune Diseases / Chloroquine / Antirheumatic Agents / COVID-19 / Hydroxychloroquine Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: English Journal: Arthritis Rheumatol Year: 2021 Document Type: Article Affiliation country: Art.41475

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Autoimmune Diseases / Chloroquine / Antirheumatic Agents / COVID-19 / Hydroxychloroquine Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: English Journal: Arthritis Rheumatol Year: 2021 Document Type: Article Affiliation country: Art.41475